Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Conditions: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET Interventions: Drug: RYZ101; Drug: Everolimus 10 mg; Drug: Sunitinib 37.5 MG; Drug: Octreotide LAR 60 MG Injection; Drug: Lanreotide 120Mg Sa Susp Inj Syringe Sponsor: RayzeBio, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer & Oncology | Carcinoid Tumor | Gastroenterology | Neurology | Research | Study